Search Results

Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.

Rhinostics Inc. is excited to announce an expanded partnership with LVL technologies GmbH, which includes Rhinostics’ reselling of LVL’s decapper instrument and LVL’s distribution of Rhinostics’ automated collection devices in Germany and Austria.

Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG (Medice – The Health Family), for Medice to market Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by Akebia to treat anemia due to chronic kidney disease (CKD), in Europe.

Calibre Scientific is pleased to announce the acquisition of DCS Innovative Diagnostik-Systeme GmbH & Co. KG (“DCS” or the “Company”), a German supplier of reagents and equipment used in immunohistochemistry for the diagnostic, research, industrial, university and hospital industries, with a focus on clinical pathology and oncology end markets.

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).

Asensus Surgical, Inc. announced that it has entered into a non-binding letter of intent with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company to engage in diligence and negotiations regarding the terms of a potential transaction whereby KARL STORZ may acquire Asensus.